Popov 2008.

Methods	RCT 2 arms Quality score: D
Participants	n = 72 Median age: 56 years ECOG 2‐3: 29%
Interventions	LV5‐FU2 oxaliplatin: oxaliplatin 85 mg/m² d 1+ folinic acid 200 mglm², as 2‐hour infusion, d 1‐2 + 5‐FU 400 mg/m², Lv. bolus d 1‐2, repeated at d 15 versus LV5‐FU2‐CDDP: cisplatin 50 mg/m², d1+ folinic acid 200 mg/m², as 2‐hour infusion, d 1‐2 + 5‐FU 400 mg/m², Lv. bolus d1‐2 + 5‐FU 600 mg/m² , 22‐hour continuous infusion d 1‐2, repeated at d 15 The maximum number of cycles foreseen was 12
Outcomes	Median overall survival Median time to progression Tumour response rates Toxicity
Notes	—
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not stated
Allocation concealment (selection bias)	Unclear risk	Not stated
Incomplete outcome data (attrition bias) efficacy	High risk	Patients receiving 4 or more cycles were evaluable for efficacy
Incomplete outcome data (attrition bias) safety	Low risk	Patients receiving 1 cycle were evaluable for toxicity
Selective reporting (reporting bias)	Low risk	Report includes all expected outcomes
Other bias	Unclear risk	N/A
Blinded review of CT/MRI‐scans?	Low risk	"Independent response review was performed by members (surgeon, medical oncologist, radiologist and pathologist) of the joint interdisciplinary committee for gastrointestinal tumors of the Institute and the University Clinic for gastrointestinal diseases. The committee members were not involved in the study"